摘要
目的:探讨尼妥珠单抗联合同步放化疗治疗局部晚期头颈鳞状细胞癌患者的临床疗效和不良反应。方法:选取2022年9月—2024年6月样本医院收治的30例局部晚期头颈鳞状细胞癌患者作为研究对象,按照随机数表法将其分为对照组和观察组,每组各15例。对照组患者给予同步放化疗治疗,观察组患者进行尼妥珠单抗联合同步放化疗治疗,比较两组患者的近期疗效和不良反应。结果:对照组患者完全缓解(CR)0、部分缓解(PR)6例、稳定(SD)3例、进展(PD)5例,客观缓解率(ORR)为60%(9/15);观察组患者CR 6例、PR 7例、SD 2例、PD 0,ORR为86%(13/15)。观察组患者近期疗效优于对照组,差异有统计学意义(P<0.05)。两组患者发生的主要不良反应为放射性黏膜炎、食欲减退、全身乏力、骨髓抑制等。结论:尼妥珠单抗联合同步放化疗较单一放化疗具有更好的疗效,且安全性良好。
Objective:There has been expert consensus that nimotuzumab has a good therapeutic effect in the treatment of locally advanced head and neck tumors.It aims to demonstrate the clinical efficacy and adverse reactions of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma patients.Methods:Thirty patients with locally advanced head and neck squamous cell carcinoma admitted to our hospital from September 2022 to June 22,2024 were randomly divided into two groups,15 cases in each group.The control group was treated with concurrent chemoradiotherapy,and the observation group was treated with nimotuzumab on the basis of the control group.The short-term efficacy and adverse reactions of the two groups were compared.Results:In the control group,0 cases had CR,6 cases had PR,3 cases had SD,and 5 cases had PD.The ORR was 60%(9/15).In the observation group,6 cases had complete response(CR),7 cases had partial response(PR),2 cases were stable(SD),and 0 cases were progressive(PD).The objective response rate(ORR)was 86%(13/15).The recent therapeutic effect of the patients in the observation froup was better than that in the control group,with statistically differences(P<0.05).The main adverse reactions in the two groups were radiation mucositis,loss of appetite,general fatigue and bone marrow suppression.Conclusion:Nimotuzumab combined with concurrent chemoradiotherapy has better efficacy and safety than chemoradiotherapy alone.
作者
刘艳辉
姜萍
赵鑫
李濛
史雪薇
李萌
金丽军
徐延龙
王瑜崴
Liu Yanhui;Jiang Ping;Zhao Xin(Mudanjiang Cancer Hospital,Mudanjiang,Heilongjiang,157000,China)
出处
《黑龙江医学》
2026年第3期321-323,共3页
Heilongjiang Medical Journal
关键词
尼妥珠单抗
局部晚期头颈鳞状细胞癌
放化疗
Nimotuzumab
Advanced head and neck squamous cell carcinoma
Chemoradiotherapy
